Capecitabine is a 5-fluorouracil (5-FU) derivative that is used widely in the treatment of colorectal cancer. The plasma ratio of dihydrouracil (UH 2 ) to uracil (Ura) is expected to gain relevance as an indirect-response biomarker to estimate the activity of dihydropyrimidine dehydrogenase (DPD). The latter is a rate-limiting enzyme in the catabolism of 5-FU in the capecitabine-based regimen. However, the relationship between the pharmacokinetics of capecitabine and the plasma UH 2 /Ura ratio is still unknown. This study evaluated the time-course alterations of the plasma UH 2 /Ura ratio in rats treated with 180 mg/kg capecitabine. The molar ratio tended to increase within 1.5 h (1.85 ± 0.76 at 1.5 h after administration of capecitabine) and gradually recovered to its initial level (1.00 ± 0.46). The results of the current study suggest that the plasma UH 2 /Ura ratio temporarily increases following administration of capecitabine, possibly related to the DPD activity levels. The plasma UH 2 /Ura ratio might assist in monitoring the alteration of DPD activity levels in capecitabine treatments.
| INTRODUCTION
5-Fluorouracil (5-FU) is a key drug that is a part of regimens for the treatment of colorectal cancer (CRC), including oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) regimens, which involve a bolus injection of 5-FU followed by long-term infusion (Lee, Beumer, & Chu, 2016; Saif, Choma, Salamone, & Chu, 2009 ). In the field of oncology, to improve chemotherapeutic outcomes, the assessment of biomarkers and therapeutic drug monitoring of 5-FU has attracted widespread interest in recent years. The ratio of dihydrouracil (UH 2 ) to uracil (Ura) in plasma is known to be an effective biomarker of dihydropyrimidine dehydrogenase (DPD) activity. The latter is the first and rate-limiting enzyme in 5-FU catabolism. Thus, this ratio is an effective means to predict 5-FU outcomes in its intravenous administration regimens, and used for an individual 5-FU dose adjustment algorithm (Gamelin et al., 1999; Lee et al., 2016) . A vast amount of data has provided evidence of the relationships between the plasma concentration of 5-FU, plasma UH 2 /Ura ratio and therapeutic outcomes (Carlsson, Odin, Gustavsson, & Wettergren, 2014; Gamelin et al., 1999; Lee et al., 2016; Wettergren, Carlsson, Odin, & Gustavsson, 2012) .
Capecitabine is an oral prodrug for 5-FU and is used widely in patients with CRC (Petrelli, Cabiddu, & Barni, 2012; Watanabe et al., 2015) . The repetitive oral administration of capecitabine plus oxaliplatin (XELOX) regimen is a standard treatment for CRC similar to the FOLFOX and FOLFIRI regimens (Watanabe et al., 2015) . Capecitabine is sequentially converted to 5-FU via a three-step enzyme activation process in the liver and tissues (Desmoulin, Gilard, MaletMartino, & Martino, 2002; Shindoh et al., 2006; Shindoh, Nakano, Yoshida, & Ishigai, 2011) . First, capecitabine is converted to 5′-deoxy-5-fluorocytidine (5′-DFCR) by carboxylesterase (CES), mainly in the liver. Then, 5′-DFCR is converted to 5′-deoxy-5-fluorouridine (5′-DFUR) by cytidine deaminase (CDA), again primarily in the liver.
Finally, 5′-DFUR is converted to 5-FU by pyrimidine nucleoside phosphorylase (PyNPase), which has been observed in high concentrations in many organs; PyNPase activity is greater in tumor tissues than in normal tissues. This unique sequential conversion enables the tion. Male Wistar rats aged 10 weeks were supplied by Nippon SLC Co., Ltd (SLC, Hamamatsu, Japan). To investigate the relationship between the plasma UH 2 /Ura ratio and DPD activity, the suppression of DPD activity by a bolus injection of 5-FU was employed, as described in our previous study (Kobuchi et al., 2016) . The rats were divided into two groups (n = 4 in each group) as follows: 180 mg/kg capecitabine (22.5 mg/ml in 1% carboxymethyl-cellulose sodium in distilled water) was orally administered with a 2 min bolus injection of saline or 60 mg/kg 5-FU (10 mg/ml in saline) into the external right jugular vein at a predetermined time of the day. The capecitabine and 5-FU dosage were determined based on previous studies (Kobuchi, Yazaki, Ito, & Sakaeda, 2018; Shindoh et al., 2006) . Blood samples (250 μl) were collected from the external left jugular vein at predetermined times after administration and transferred to heparinized centrifuge tubes. After centrifugation of the blood samples at 14,000 × g for 15 min, the plasma samples were stored at −80°C until analysis. Plasma concentrations of capecitabine, 5′-DFCR, 5′-DFUR, 5-FU, Ura and UH 2 were determined by LC-MS/MS method, which was conducted and reported in our previous report Kobuchi et al., 2018) .
| Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis (NCA) was performed to obtain pharmacokinetic parameters. The time (T max ) at which the plasma concentrations reached a maximum value (C max ) was determined from the plasma concentrations versus time data. The elimination half-life (t 1/2 ), the area under the plasma concentration-time curve from 0 h to infinity (AUC 0-∞ ), the apparent total plasma clearance (CL tot /F), and the apparent distribution volume (V d /F) were determined by using the NCA analysis program of the WinNonlin® Version 6.3 software (Certara USA, Inc., USA). The CES and CDA activity were estimated using the AUC 0-∞ ratio of 5′-DFCR/ capecitabine and 5′-DFUR/5′-DFCR, respectively. However, the PyNPase activity in rats administered a 5-FU bolus injection could not be estimated using the AUC 0-∞ ratio of 5-FU/5′-DFUR due to the loading dose of 5-FU.
| Statistical analysis
All values are expressed as mean ± standard deviation (SD). Two-group comparisons were performed using the Student's unpaired t-test. The differences between the means were considered statistically significant at p < 0.05.
| RESULTS AND DISCUSSION
The sequential conversion of capecitabine to 5-FU was observed in rats ( Figure 1a) , which was consistent with the findings of a previous study (Kobuchi et al., 2018) . The UH 2 /Ura molar ratio in the rats treated with capecitabine tended to increase (1.85 ± 0.76 at 1.5 h after administration of capecitabine), and then gradually recovered to its initial level (1.00 ± 0.46) (Figure 1b) , raising the possibility of an increase in hepatic DPD activity. To test this hypothesis, the activity of DPD was evaluated in vitro using hepatic cytosol obtained within 2 h after administration of capecitabine. However, the degradation rate of 5-FU could not be accurately evaluated due to the presence of 5-FU, which was metabolized from capecitabine. Alternatively, to verify the hypothesis, the plasma UH 2 /Ura ratio was evaluated after the administration of capecitabine plus a bolus injection of 5-FU, which suppresses the DPD activity and maintains a low plasma UH 2 / Ura ratio (Kobuchi et al., 2016) . There was a decrease in the plasma UH 2 /Ura ratio; however, the ratio rapidly recovered to its initial level (Figure 1b) . Although the results suggest an increase in the CDA level (Figure 1c) , the bolus injection of 5-FU did not change the mean plasma level of 5′-DFCR and 5′-DFUR ( Figure 1a and Table 1 ).
Additionally, the slow elimination of 5-FU from the blood was not observed. Overall, the results proved the hypothesis that the hepatic DPD activity can be increased in rats after the administration of capecitabine.
High DPD activity has been reported. For instance, Tateishi et al.
(1999) reported that the DPD activity and protein levels in rat models of hepatic failure were higher than those in their controls, although the mechanisms were not clear. In 1,2-dimethylhydrazine-induced CRC model rats, the hepatic DPD activity and the plasma UH 2 /Ura ratio were higher than those in the control rats (Kobuchi, Ito, et al., Each value represents the mean ± SD of four rats.
*p < 0.05 statistically significant difference against rats treated without a bolus injection of 5-FU.
human carcinoma cells was higher than that in normal cells (Miyazaki et al., 2006) . These observations and the data of the present study raised at least two possibilities. First, temporary hepatic failure might be induced by the administration of capecitabine, increasing the DPD activity and the plasma UH 2 /Ura ratio. Olayinka, Ola, Ore, and
Adeyemo (2017) recently reported that the administration of capecitabine could damage the liver cells and increase specific catalytic protein levels. Second, higher DPD activity in cancer condition suggests the need for the application of an individual dosing strategy of capecitabine. However, to obtain a solid conclusion on the facilitation of hepatic DPD activity, further investigations are needed.
Studies investigating the relationship between the pharmacokinetics of capecitabine and the plasma UH 2 /Ura ratio are limited. To the best of our knowledge, there has been only one study by Jacobs et al. (2016) in this regard, conducted on a single patient. Both plasma Ura and UH 2 levels decreased within the first hour after administration of capecitabine, followed by an increase and subsequent stabilization. The authors concluded that these alterations might be caused by competition between Ura and UH 2 and capecitabine metabolites for the same enzymes. However, further research is needed to draw solid conclusions regarding this. The present study results suggest that the possible increase in the DPD activity with the administration of capecitabine also affects the changes in the Ura and UH 2 plasma levels.
Alternatively, repetitive exposure of 5-FU can suppress the DPD activity, and this can be assessed by the plasma UH 2 /Ura ratio Kobuchi, Kuwano, et al., 2013) . In clinical studies on capecitabine, an increase of 5-FU exposure after multiple administration of capecitabine has been reported, whereas there was no difference in the pharmacokinetics and no clinically significant accumulation of capecitabine and its metabolites (Hyodo et al., 2006; Saeki et al., 2005) . These observations suggest that the plasma Ura and UH 2 levels are affected by not only the competition between nucleic acid base and capecitabine metabolites, but also changes in the DPD activity after capecitabine treatment. Therefore, balanced DPD activity can be an important factor determining the plasma level of 5-FU in patients treated with the capecitabine-based regimen. Additionally, the plasma UH 2 /Ura ratio can serve as a useful marker to estimate the DPD activity during repeated administration of capecitabine.
However, a limitation of the present study is the animal experiments were conducted after a single administration of capecitabine; further studies with repeated dosing in animals and patients are necessary.
| CONCLUSIONS
Overall, we found that the plasma UH 2 /Ura ratio temporarily increased following capecitabine administration, possibly because of the changes in DPD activity. Monitoring of the plasma UH 2 /Ura ratio might be useful to evaluate the changes in DPD activity with capecitabine treatments. Our results can help to develop personalized medicine in cancer chemotherapy. Moreover, our findings might have important implications for individualized dose determination of capecitabine. However, to identify the relationship between the plasma UH 2 /Ura ratio and the pharmacological effects of capecitabine, further studies are needed.
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